And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda, for the moment, is rather modest. We hope to catch up on some sundry chores, spend time with our short person, and possibly visit the Pharmalot ancestors. And what about you? This may be a good time to take in a moving picture. For those with a keen sense of discipline, you can self-flagellate by readying your taxes. Or you could catch up on the steady stream of presidential tweets, such as they are. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

A focus on fewer diseases, along with cuts in labs and staff, has yielded a more than fourfold increase in research productivity at AstraZeneca (AZN)Reuters writes. Why? There was a marked drop in the number of projects started at the discovery stage, with the total falling to just 76 in 2012 to 2016 from 287 in 2005 to 2010. “We’re working on far fewer programs and the probability of success on those programs is going up,” says one AstraZeneca exec.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • When you lose $7 billion in sales off your blockbuster drug Crestor, with nothing in the pipeline to compensate, it does tend to put a crimp in your R&D budget.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy